The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05A | Antipsychotics | |
| 4 | N05AX | Other antipsychotics | |
| 5 | N05AX12 | Aripiprazole |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 15 mg |
| PAREN - Parenteral | 15 mg |
| PAREN - Parenteral (depot) | 13.2 mg |
| Active Ingredient | Description | |
|---|---|---|
| Aripiprazole |
It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ABILIFY Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ABILIFY Tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
